GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » Cyclically Adjusted Price-to-FCF

ValiRx (LSE:VAL) Cyclically Adjusted Price-to-FCF : (As of Apr. 27, 2024)


View and export this data going back to 2000. Start your Free Trial

What is ValiRx Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


ValiRx Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for ValiRx's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx Cyclically Adjusted Price-to-FCF Chart

ValiRx Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ValiRx Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ValiRx's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, ValiRx's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ValiRx's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ValiRx's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where ValiRx's Cyclically Adjusted Price-to-FCF falls into.



ValiRx Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

ValiRx's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec22 is calculated as:

For example, ValiRx's adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec22 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec22 (Change)*Current CPI (Dec22)
=-0.022/125.3000*125.3000
=-0.022

Current CPI (Dec22) = 125.3000.

ValiRx Annual Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201312 -19.838 99.200 -25.057
201412 -17.519 99.900 -21.973
201512 -11.858 100.400 -14.799
201612 -9.920 102.200 -12.162
201712 -2.176 105.000 -2.597
201812 -1.002 107.100 -1.172
201912 -0.241 108.500 -0.278
202012 -0.053 109.400 -0.061
202112 -0.019 114.700 -0.021
202212 -0.022 125.300 -0.022

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ValiRx  (LSE:VAL) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


ValiRx Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of ValiRx's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


ValiRx (LSE:VAL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » Cyclically Adjusted Price-to-FCF
Traded in Other Exchanges
Address
4 Barling Way, Eliot Park Innovation Centre, Nuneaton, GBR, CV10 7RH
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, NAV3 for the cancer screening test, and VAL401 for lung cancer.